Quarterly report [Sections 13 or 15(d)]

Unaudited Condensed Consolidated Statements of Operations

v3.25.4
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Research and development $ 1,344,182 $ 5,716,830
General and administrative 4,079,833 5,227,113
Total operating expenses 5,424,015 10,943,943
Gain on sale of ENTADFI® assets 0 695,216
Operating loss from continuing operations (5,424,015) (10,248,727)
Non-operating income (expenses):    
Gain on extinguishment of debt 0 8,624,778
Change in fair value of equity securities (120,078) (349,078)
Other income, net 211,514 163,124
Total non-operating income 91,436 8,438,824
Net loss from continuing operations (5,332,579) (1,809,903)
Net loss from discontinued operations, net of taxes 0 (7,135,444)
Net loss $ (5,332,579) $ (8,945,347)
Net loss from continuing operations per basic and diluted common shares and pre-funded warrants outstanding (in dollars per share) $ (0.26) $ (0.12)
Net loss from discontinued operations per basic and diluted common shares and pre-funded warrants outstanding (in dollars per share) 0 (0.49)
Net loss per basic and diluted common shares and pre-funded warrants outstanding (in dollars per share) $ (0.26) $ (0.61)
Basic and diluted weighted average common shares and pre-funded warrants outstanding (in shares) 20,311,190 14,638,392